790 related articles for article (PubMed ID: 16571093)
1. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
2. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
3. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
4. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
[TBL] [Abstract][Full Text] [Related]
5. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
6. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
7. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.
Vitti P; Rago T; Chiovato L; Pallini S; Santini F; Fiore E; Rocchi R; Martino E; Pinchera A
Thyroid; 1997 Jun; 7(3):369-75. PubMed ID: 9226205
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
10. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
11. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
12. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
[TBL] [Abstract][Full Text] [Related]
13. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
14. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
15. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
16. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
[TBL] [Abstract][Full Text] [Related]
17. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
18. Serum thyrotropin-receptor autoantibodies levels after I therapy in Graves' patients: effect of pretreatment with methimazole evaluated by a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
Eur J Endocrinol; 2004 Oct; 151(4):467-74. PubMed ID: 15476447
[TBL] [Abstract][Full Text] [Related]
19. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
20. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
Gauna AT; Guillén CE; Sartorio GC; Soto RJ
Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]